Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic asthma

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 3, 2009, Pages 254-259

  Ariano, Renato ^a   Berto, Patrizia ^b   Incorvaia, Cristoforo ^c   Di Cara, Giuseppe ^d   Boccardo, Rachele ^d   La Grutta, Stefania ^e   Puccinelli, Paola ^f   Frati, Franco ^d,f  

^a Ospedale di Bordighera Azienda Sanitaria Locale 1   (Italy)

^b Pbe Consulting   (Italy)

^c PARKINSON INSTITUTE   (Italy)

^d Institute of Pediatrics   (Italy)

^e CNR   (Italy)

^f Medical and Scientific Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BUDESONIDE; CETIRIZINE; EYE DROPS; FLUTICASONE; FORMOTEROL; HOUSE DUST ALLERGEN; METHYLPREDNISOLONE; NEDOCROMIL; NOSE SPRAY; OXITROPIUM BROMIDE; OXYMETAZOLINE; SALBUTAMOL; SALMETEROL; SPAGLUMIC ACID; STALORAL 300; THEOPHYLLINE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; ECONOMIC ASPECT; EDEMA; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RHINITIS; SCORING SYSTEM; SYMPTOM;

EID: 70349448206     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60190-1     Document Type: Article

References (34)

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet. 1998; 351:1225-1232.
2. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study survey of parents and offspring. BMJ. 2000;321: 88-92. (Pubitemid 30438485)
3. Mackowiak JI. The health and economic impact of rhinitis. Am J Manag Care. 1997;3:S8-S18.
4. Law AW, Reed SD, Sundy J, et al. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2003;111:296-300.
5. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis. Pharmacoeconomics. 2004;22:345-361.
6. Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-year retrospective study. Eur Respir J. 2003;21:116-122. (Pubitemid 36150311)
7. O'Connell EJ. The burden of atopy and asthma in children. Allergy. 2004;59(suppl 78):7-11.
8. Weiss KB, Sullivan SD. The health and economics of asthma and rhinitis, I: assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8. (Pubitemid 32105235)
9. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-1218.
10. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53:11-18.
11. Wilson DR, Torres-Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005; 60:4-12.
12. Passalacqua G, Valovirta E, van Weissenbruch R, Frati F, Incorvaia C, Puccinelli P. Sublingual Specific Immunotherapy: From Scientific Background to Clinical Practice. Milan, Italy: Sinergie; 2007.
13. Buchner K, Siepe M. Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten. Allergo J. 1995;4:156-163.
14. Fischer P. Therapie des allergisches Asthma: Die spezifische Hyposensibilierung kann helfen Kosten in Milliardenhohe einzusparen. Laryngorhinootologie. 1995;74:28.
15. Kumar P, Kamboj S, Rao P, et al. The cost of acre and quality of life in patients with allergic rhinitis on allergen immunotherapy. Allergy Clin Immunol Int. 1997;9:133-135.
16. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996;334:501-506.
17. Donohue J, Greneider DK, Connor-Lake L, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 1999;82:339-347. (Pubitemid 29203282)
18. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000;17:37-52.
19. Le Pen C, Rumeau-Pichen C, Lillin H. L'impact de l'immunothérapie specifique sur le couts directs de la maladie allergique: une etude pragmatique. Rev Francaise d'Allergologie et d'Immunologie Clin. 1997;37:11-14. (Pubitemid 27234498)
20. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr). 2005;33:296-302. (Pubitemid 47250520)
21. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2006;27: 159-163.
22. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37:303-308. (Pubitemid 41599772)
23. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) Study. Ann Allergy Asthma Immunol. 2006;97: 615-621. (Pubitemid 44851458)
24. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass pollen-induced allergy: results from the SIMAP database study. Curr Med Res Opin. 2008;24: 261-266. (Pubitemid 351160258)
25. Omnes LF, Bousquet J, Scheinmann P, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol. 2007;39:148-156. (Pubitemid 46954542)
26. GINA Workshop Report: Global Strategy for Asthma Management and Prevention. 2002. NIH publication 02-3659.
27. Ministero della Sanità. Nomenclatore Tariffario delle prestazioni ambulatoriali DM 22.7.96. Gazzetta Ufficiale. September 14, 1996:16.
28. Informatore Farmaceutico: Annuario Italiano dei Medicinali e dei Laboratori. Milan, Italy: Edizioni OEMF International sri; 2006.
29. Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62:367-372. (Pubitemid 46398791)
30. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585-589.
31. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen-induced rhinoconjunctivitis: a northern European perspective. Clin Exp Allergy. 2007;37:772-779. (Pubitemid 46646783)
32. Canonica GW, Poulsen PB, Vestenbaek U. Cost-effectiveness of GRAZAX for prevention of grass pollen-induced rhinoconjunctivitis in southern Europe. Respir Med. 2007;101:1885-1894. (Pubitemid 47163544)
33. Dal Negro R, Berto P, Tognella S, Quareni L; Global Outcomes in Lung Disease Study Group. Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis. 2002;57:3-9.
34. Gidaro G, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy. 2005;35:565-571. (Pubitemid 40769278)